A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis.
Phase of Trial: Phase IV
Latest Information Update: 23 Dec 2015
At a glance
- Drugs Bortezomib (Primary) ; Thalidomide (Primary) ; Cyclophosphamide; Dexamethasone
- Indications Amyloid light-chain amyloidosis
- Focus Therapeutic Use
- 23 Dec 2015 New trial record